Immune clues could predict desmoid tumor behavior

NCT ID NCT07496242

Recruiting now Knowledge-focused Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the immune system of 200 people with desmoid tumors, either under observation or receiving treatment. Researchers will analyze blood and tumor samples to find markers that may predict whether the tumor shrinks, stays stable, or grows. The goal is to better understand the disease, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DESMOID-TYPE FIBROMATOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

desmoid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DESMOID-TYPE FIBROMATOSIS

Contacts and locations

Locations

Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone"
NOT_YET_RECRUITING

Palermo, Italy
Azienda Ospedaliero Universitaria Careggi
NOT_YET_RECRUITING

Florence, Italy
Azienda Usl Toscana centro
NOT_YET_RECRUITING

Florence, Italy
Erasmus University Medical Centre
NOT_YET_RECRUITING

Rotterdam, Netherlands
Fondazione IRCCS Istituto Nazionale dei Tumori
RECRUITING

Milan, 20133, Italy
IRCCS Istituto Oncologico Veneto IOV
NOT_YET_RECRUITING

Padova, Italy
IRCCS Istituto di Candiolo Fondazione del Piemonte per l'Oncologia
NOT_YET_RECRUITING

Candiolo, Italy
Università Campus Bio-Medico
NOT_YET_RECRUITING

Rome, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.